Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation TCT 2015

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Presenter: Steven R. Bailey, Patrick W. Serruys, Renato Valenti

October 15, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Presenter: Eric Boersma, E. Magnus Ohman, Giuseppe Biondi-Zoccai

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

News Conference News TCT 2014

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

September 15, 2014

News Conference News TCT 2014

Expert Discusses Potential Role for Platelet Function, Genetic Testing

September 15, 2014

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Advertisement

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Lessons From the TAXUS Liberté/Prasugrel Substudy

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

Expert Discusses Potential Role for Platelet Function, Genetic Testing

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content